Promega Corporation, Wisconsin, United States
Kristin received her Ph.D. in Biomedical Engineering from the University of Wisconsin – Madison studying invasion and metastasis in breast cancer. She joined Promega in 2014 and very quickly worked to develop a platform of technologies aimed to characterize the cellular kinetics, potency, and mechanism of action of novel protein degrader compounds. Kristin is currently a group leader focused on expanding these technologies to enable further insights in bifunctional degrader development, screening, and SAR, as well as in new modalities for TPD and induced proximity.
Disclosure information not submitted.
Wednesday, February 9, 2022
9:00 AM – 10:00 AM